| Title： | Expert Consensus on PARPi Interaction Management |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Administration |
| Countries and regions： | China |
| Guidelines users： | |
| Evidence classification method： | Rating system were determined by this expert group |
| Development unit： | Zhejiang Provincial People's Hospital |
| Registration time: | 2022-09-12 |
| Registration number： | PREPARE-2022CN596 |
| Purpose of the guideline: | Most PARPi are metabolized by liver enzymes, and there are extensive drug interactions with other drugs, which are easy to be ignored in clinical use, resulting in increased toxicity or decreased efficacy. This consensus systematically summarizes the interaction of PARPi listed in China and forms relevant recommendations to provide reference for the safe and rational use of PARPi in clinic. |
